Explore the latest news from Khondrion and its team.
Khondrion, a clinical-stage biopharmaceutical companypioneering therapies for primary mitochondrial disease (PMD), today announced it has beenawarded an Innovation Credit of up to €5 million from the Netherlands Enterprise Agency, agovernment agency that supports entrepreneurs...
The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion...
52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...
Khondrion, a clinical-stage biopharmaceutical company specializing in mitochondrial disease therapies,...
NIJMEGEN, The Netherlands – October 29, 2024: Khondrion, a pioneering clinical-stage biopharmaceutical company focused on developing transformative...
How did you cross paths with Khondrion? I heard about Khondrion from international colleagues and was made aware that this company was focused on...
2020 – A Year in Review As a new year approaches, Khondrion’s CEO Jan Smeitink reflects on 2020 and the progress Khondrion has made in its research...
1. Tell us about your role as Chief Early Development Officer at Khondrion. There are a lot of different aspects to my role. I help to steer the...
Estimated to affect more than 400 million people around the world, diabetes is one of the most common chronic disorders, with a range of different...
Mitochondrial diseases are a clinically, biochemically and genetically heterogeneous group of disorders. Signs, symptoms and the organs involved can...
Simple functions such as blinking and breathing are actions that we take for granted. However, for those living with Leigh...
